Skip to main content
Signal8

Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations

$PLXPress releaseNov 9, 2026, 6:45 AM ETRead the release

Protalix presented new individual-patient PK/PD data at ACR Convergence 2026 showing that higher single doses of PRX-115 kept plasma uric acid below the 6.0 mg/dL therapeutic target for extended periods. At the 36 mg dose, mean uric acid stayed below target for up to 12 weeks after a single infusion, with PRX-115 plasma levels remaining measurable for up to 85 days, supporting less frequent dosing.

Key figures

Drug Name
PRX-115 (recombinant PEGylated uricase)
Phase Of Trial
Phase 1 (single ascending dose); Phase 2 RELEASE ongoing
Urate target
6.0 mg/dL
Phase1 cohorts
18 mg, 24 mg, 36 mg (6 participants per cohort)
Release topline
second half of 2027
Phase2 release arms
five arms of 30 patients each, fixed 36 mg dose
Prx115 detectable days
up to 85 days
Duration below target 36mg
up to 12 weeks after a single infusion
Us uncontrolled gout patients
180000

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    PLX: Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations — AI Analysis | Signal8